European Consumers And GI Disorders

16 December 1996

Almost a third of Europeans suffer from gastrointestinal problems, yet fewer than half of them will consult a doctor, says Gastro-Intestinal Products in the European Self-Medical Market to 2006, a new 14-country study from James Dudley Management.

The European market for non-prescription bound GI products is put at $2.1 billion, or over 13% of the total European non-prescription bound market, it says, with over-the-counter purchases accounting for 63% of industry sales. France represents 24% of the total, followed by Germany with 21% and Italy with 13%. Laxatives are the largest subcategory, with 35% of the market, followed by antacids with 27% and antidiarrheals on 14%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight